142 related articles for article (PubMed ID: 22044804)
21. Cancer treatment-induced bone loss in breast and prostate cancer.
Saad F; Adachi JD; Brown JP; Canning LA; Gelmon KA; Josse RG; Pritchard KI
J Clin Oncol; 2008 Nov; 26(33):5465-76. PubMed ID: 18955443
[TBL] [Abstract][Full Text] [Related]
22. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
[TBL] [Abstract][Full Text] [Related]
23. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Hadji P; Bundred N
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
[TBL] [Abstract][Full Text] [Related]
24. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
25. Denosumab: benefits of RANK ligand inhibition in cancer patients.
Lipton A; Jacobs I
Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
[TBL] [Abstract][Full Text] [Related]
26. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
Gnant M; Dubsky P; Fitzal F; Blaha P; Schoppmann S; Steger G; Marth C; Samonigg H; Hüttner K; Fohler H; Ruecklinger E; Jakesz R; Greil R;
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S18-27. PubMed ID: 19561003
[TBL] [Abstract][Full Text] [Related]
27. Prevention of osteoporosis as a consequence of aromatase inhibitor therapy in postmenopausal women with early breast cancer: rationale and design of a randomized controlled trial.
Kilbreath S; Refshauge KM; Beith J; Ward L; Sawkins K; Paterson R; Clifton-Bligh P; Sambrook PN; Simpson JM; Nery L
Contemp Clin Trials; 2011 Sep; 32(5):704-9. PubMed ID: 21570487
[TBL] [Abstract][Full Text] [Related]
28. Aromatase inhibitors and bone health.
Bundred NJ
Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
[TBL] [Abstract][Full Text] [Related]
29. New developments for treatment and prevention of bone metastases.
Body JJ
Curr Opin Oncol; 2011 Jul; 23(4):338-42. PubMed ID: 21519257
[TBL] [Abstract][Full Text] [Related]
30. Cancer treatment-induced bone loss in premenopausal women: a need for therapeutic intervention?
Hadji P; Gnant M; Body JJ; Bundred NJ; Brufsky A; Coleman RE; Guise TA; Lipton A; Aapro MS
Cancer Treat Rev; 2012 Oct; 38(6):798-806. PubMed ID: 22429722
[TBL] [Abstract][Full Text] [Related]
31. Treatment of osteoporosis in women intolerant of oral bisphosphonates.
Aspray TJ; Francis RM
Maturitas; 2012 Jan; 71(1):76-8. PubMed ID: 22079368
[TBL] [Abstract][Full Text] [Related]
32. Bone mineral density deficits in survivors of childhood cancer: long-term follow-up guidelines and review of the literature.
Wasilewski-Masker K; Kaste SC; Hudson MM; Esiashvili N; Mattano LA; Meacham LR
Pediatrics; 2008 Mar; 121(3):e705-13. PubMed ID: 18310191
[TBL] [Abstract][Full Text] [Related]
33. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
34. The adherence to practice guidelines in the assessment of bone health in women with chemotherapy-induced menopause.
Tham YL; Sexton K; Weiss HL; Elledge RM; Friedman LC; Kramer RM
J Support Oncol; 2006 Jun; 4(6):295-8, 304. PubMed ID: 16805332
[TBL] [Abstract][Full Text] [Related]
35. [Cancer treatment-induced bone loss. Treatment for breast cancer].
Yamada K; Kohno N
Clin Calcium; 2008 Apr; 18(4):507-17. PubMed ID: 18379033
[TBL] [Abstract][Full Text] [Related]
36. Osteopenia and osteoporosis in women with breast cancer.
Ramaswamy B; Shapiro CL
Semin Oncol; 2003 Dec; 30(6):763-75. PubMed ID: 14663777
[TBL] [Abstract][Full Text] [Related]
37. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
Lipton A
Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
[TBL] [Abstract][Full Text] [Related]
38. Bone targeted therapy in breast cancer: present and future.
Huober J; Thürlimann B
Crit Rev Oncol Hematol; 2010 Apr; 74 Suppl 1():S7-10. PubMed ID: 20427030
[No Abstract] [Full Text] [Related]
39. Osteoporosis risk in premenopausal women.
Vondracek SF; Hansen LB; McDermott MT
Pharmacotherapy; 2009 Mar; 29(3):305-17. PubMed ID: 19249949
[TBL] [Abstract][Full Text] [Related]
40. Safety considerations for use of bone-targeted agents in patients with cancer.
Mortimer JE; Pal SK
Semin Oncol; 2010 Jun; 37 Suppl 1():S66-72. PubMed ID: 20682374
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
